Open controlled clinical trial. Hospitalized pediatric patients with COVID-19 will be included. Upon admission to hospital serum determination of vitamin D, interleukins, ferritin and Dimer D will be performed. Subsequently, randomization will be performed to identify which group the patient belongs. Adverse effects will be evaluated on a daily basis. Serum levels of interleukin (IL) -2, 6, 7,10, ferritin and dimer-D will be taken at the beginning of hospitalization and on the 7th day after admission. It will be recorded if the patient presents deterioration of the respiratory function that requires endotracheal intubation and / or admission to intensive care and / or if he dies, and at what time of hospitalization does this outcome occur. The study will culminate when the patient is discharged from hospitalization.
Hospitalized pediatric patients with COVID-19 will be included. The diagnosis of COVID-19
performed through RT-PCR. Upon admission to hospital, a serum determination of Vitamin D,
interleukins, ferritin and dimer-D will be performed. Subsequently, randomization will be
performed to identify which group the patient belongs to. In case of being in the vitamin D
group, in children under 12 months they will be given 1000U and in children over 12 months
they will be given 2000U every 24 hours orally. Adverse effects will be evaluated on a daily
basis. Subsequently, serum levels of interleukin (IL) -2, 6, 7,10, ferritin and dimer-D will
be taken on day 7 of admission. It will be recorded if the patient presents deterioration of
the respiratory function that requires endotracheal intubation and / or admission to
intensive care and / or if he dies, and at what time of hospitalization does this outcome
occur. The study will culminate when the patient is discharged from hospitalization. On the
day of hospital discharge, a blood sample will be taken to determine vitamin D.
Drug: Cholecalciferol
1000U or 2000U every 24 hours orally
Other Name: vitamin D
Inclusion criteria
1. Age over 1 month and under 17 years
2. Confirmed diagnosis of COVID-19 infection with the results of real-time PCR
3. That they agreed to participate in the study.
4. That the patient tolerates the enteral route
Exclusion criteria
1. Have received vitamin D in the four weeks prior to hospitalization.
Hospital Centro Medico Nacional Siglo XXI
Mexico City, Distrito Federal, Mexico
JESSIE ZURITA-CRUZ, Principal Investigator
Coordinación de Investigación en Salud, Mexico